Hologic, Inc. (NASDAQ:HOLX) Holdings Lowered by Robeco Institutional Asset Management B.V.

Robeco Institutional Asset Management B.V. cut its stake in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 47.0% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 84,580 shares of the medical equipment provider's stock after selling 75,067 shares during the period. Robeco Institutional Asset Management B.V.'s holdings in Hologic were worth $5,225,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Norges Bank purchased a new stake in Hologic during the fourth quarter worth approximately $133,414,000. Boston Partners increased its position in Hologic by 81.0% during the 4th quarter. Boston Partners now owns 3,580,519 shares of the medical equipment provider's stock worth $257,959,000 after purchasing an additional 1,602,463 shares during the period. Champlain Investment Partners LLC acquired a new stake in Hologic in the fourth quarter valued at $79,291,000. Redwood Wealth Management Group LLC acquired a new stake in shares of Hologic in the first quarter valued at about $3,534,000. Finally, Northern Trust Corp grew its holdings in shares of Hologic by 26.9% in the 4th quarter. Northern Trust Corp now owns 3,147,420 shares of the medical equipment provider's stock worth $226,898,000 after acquiring an additional 668,086 shares during the period. Hedge funds and other institutional investors own 94.73% of the company's stock.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Hologic in a report on Tuesday, May 27th. Evercore ISI lowered their target price on shares of Hologic from $65.00 to $62.00 and set an "in-line" rating for the company in a report on Friday, May 2nd. Wall Street Zen lowered Hologic from a "buy" rating to a "hold" rating in a research note on Monday, May 5th. Raymond James Financial restated an "outperform" rating and set a $71.00 target price (down previously from $90.00) on shares of Hologic in a report on Friday, May 2nd. Finally, Morgan Stanley reduced their target price on shares of Hologic from $77.00 to $65.00 and set an "equal weight" rating on the stock in a research report on Monday, May 5th. Twelve investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the company presently has an average rating of "Hold" and an average target price of $77.42.

Insider Activity at Hologic

In other news, Director Martin D. Madaus acquired 5,445 shares of the business's stock in a transaction dated Wednesday, May 7th. The stock was acquired at an average price of $55.24 per share, for a total transaction of $300,781.80. Following the completion of the acquisition, the director directly owned 5,445 shares in the company, valued at $300,781.80. This represents a ∞ increase in their position. The acquisition was disclosed in a filing with the SEC, which is available through this link. 1.88% of the stock is owned by corporate insiders.

Hologic Stock Performance

Shares of NASDAQ:HOLX traded up $0.17 during trading on Tuesday, hitting $65.33. 2,165,228 shares of the company traded hands, compared to its average volume of 2,365,981. The stock has a market capitalization of $14.56 billion, a price-to-earnings ratio of 27.57, a PEG ratio of 2.38 and a beta of 0.55. The business's fifty day moving average is $60.17 and its 200-day moving average is $63.84. The company has a quick ratio of 2.52, a current ratio of 3.24 and a debt-to-equity ratio of 0.54. Hologic, Inc. has a one year low of $51.90 and a one year high of $84.67.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. The business had revenue of $1.01 billion during the quarter, compared to the consensus estimate of $1 billion. Hologic had a return on equity of 19.71% and a net margin of 13.83%. The business's revenue was down 1.2% on a year-over-year basis. During the same period in the previous year, the firm posted $1.03 earnings per share. As a group, equities analysts predict that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.